Streamex Corp. current report, 29 April 2020

Full document

Business Context and Reporting Period

This Form 8-K was filed by BioSig Technologies, Inc. (not Streamex Corp.) on April 29, 2020. The registrant is a Delaware corporation with its principal executive offices in Westport, Connecticut. The filing discloses a material scientific development regarding its majority-owned subsidiary, ViralClear Pharmaceuticals, Inc.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory disclosure under Item 7.01 and does not contain financial statements or quantitative financial data.

Material Changes and Scientific Developments

  • Pre-Clinical Data Submission: An article titled "The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro" has been submitted to a peer-reviewed life sciences journal.
  • Key Finding: Merimepodib, a broad-spectrum anti-viral candidate developed by ViralClear, demonstrated strong activity against COVID-19 in cell cultures when combined with remdesivir.
  • Research Context: The data was generated under contract with the Galveston National Laboratory at The University of Texas Medical Branch.
  • Development Status: The pharmaceutical is currently undergoing extensive pre-clinical testing. ViralClear intends to pursue FDA-approved clinical trials for the treatment of COVID-19.

Guidance, Outlook, and Risks

Outlook: Management intends to advance Merimepodib into clinical trials for COVID-19 treatment based on the in vitro results.

Risks and Contingencies:

  • The data presented is pre-clinical (in vitro) and does not guarantee efficacy in humans.
  • The filing explicitly states that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not intended to constitute a determination of materiality under Regulation FD.
  • Success depends on the outcome of future FDA-approved clinical trials.

Investor Verification Checklist

  • Verify the publication status of the submitted article in the peer-reviewed journal.
  • Confirm the timeline and design of the planned FDA-approved clinical trials for Merimepodib.
  • Review the company's cash position and funding requirements to support the transition from pre-clinical to clinical phases.
  • Assess the competitive landscape for Merimepodib and Remdesivir combinations in the treatment of SARS-CoV-2.